Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

v-Jun sensitizes cells to apoptosis by a mechanism involving mitochondrial cytochrome C release

Abstract

v-Jun shares the ability of the Myc, E1A, and E2F oncogenes to both sustain cell cycle progression and promote apoptosis in the absence of mitogenic stimulation. To gain an insight into the mechanism of apoptosis sensitization, we examined the possible involvement of key regulatory proteins previously implicated in oncogene-induced cell death during v-Jun-induced apoptosis triggered by serum withdrawal. We observed that ectopic expression of the anti-apoptotic Bcl-2 protein, or of two downstream effectors of growth factor signalling, v-PI 3-Kinase and v-Src, partially or completely suppressed apoptosis. Apoptosis was also observed in the presence of serum growth factors when endogenous PI3K activity was blocked using the synthetic inhibitor LY294002, further suggesting an important role for PI3-K in cell survival. Cytochrome C was released into the cytosol of apoptotic v-Jun expressing cells, and this release was inhibited by Bcl-2, suggesting an important role for mitochondrial dysfunction in v-Jun induced apoptosis. In contrast, inhibition of Fas signalling using dominant negative FADD did not inhibit apoptosis, nor was there any evidence for accumulation or activation of p53 in v-Jun transformed cells. Consistent with this latter observation, inhibition of p53 function by HPV16 E6 protein had no effect on v-Jun induced cell death. Taken together, these results suggest that mitochondrial dysfunction is an important component of the mechanism through which v-Jun sensitizes cells to apoptosis, but that the apoptotic signals elicited by v-Jun upstream of the mitochondria do not depend on increased levels of p53 activity or Fas signalling.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Bates S and Vousden KH. . 1999 Cell. Mol. Life Sci. 55: 28–37.

  • Bossy-Wetzel E, Bakiri L and Yaniv M. . 1997 EMBO J. 16: 1695–1709.

  • Brown JP and Pagano M. . 1997 Biochim. Biophys. Acta. 1332: 1–6.

  • Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME. . 1999 Cell 96: 857–868.

  • Carpenter CL and Cantley LC. . 1996 Curr. Opin. Cell. Biol. 8: 153–158.

  • Clark W, Black EJ, MacLaren A, Kruse U, LaThangue N, Vogt PK and Gillespie DA. . 2000 Mol. Cell. Biol. 20: 2529–2542.

  • Clark W and Gillespie DA. . 1997 Cell Growth Differ. 8: 371–380.

  • Crouch DH, Fincham VJ and Frame MC. . 1996 Oncogene 12: 2689–2696.

  • Dang CV and Semenza GL. . 1999 Trends Biochem. Sci. 24: 68–72.

  • de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ and Lowe SW. . 1998 Genes Dev. 12: 2434–2442.

  • DeGregori J, Leone G, Miron A, Jakoi L and Nevins JR. . 1997 Proc. Natl. Acad. Sci. USA 94: 7245–7250.

  • Ellis RE, Yuan JY and Horvitz HR. . 1991 Annu. Rev. Cell. Biol. 7: 663–698.

  • Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC. . 1992 Cell 69: 119–128.

  • Gorczyca W, Gong J, Ardelt B, Traganos F and Darzynkiewicz Z. . 1993 Cancer Res. 53: 3186–3192.

  • Gross A, McDonnell JM and Korsmeyer SJ. . 1999 Genes Dev. 13: 1899–1911.

  • Harrington EA, Fanidi A and Evan GI. . 1994 Curr. Opin. Genet. Dev. 4: 120–129.

  • Hermeking H and Eick D. . 1994 Science 265: 2091–2093.

  • Hoffman B and Liebermann DA. . 1998 Oncogene 17: 3351–3357.

  • Hueber AO, Zornig M, Lyon D, Suda T, Nagata S and Evan GI. . 1997 Science 278: 1305–1309.

  • Juin P, Hueber AO, Littlewood T and Evan G. . 1999 Genes Dev. 13: 1367–1381.

  • Kennedy SG, Kandel ES, Cross TK and Hay N. . 1999 Mol. Cell. Biol. 19: 5800–5810.

  • Kerr JF, Wyllie AH and Currie AR. . 1972 Br. J. Cancer 26: 239–257.

  • Kilbey A, Black EJ, Unlu M and Gillespie DA. . 1996 Oncogene 12: 2409–2418.

  • Lenahan MK and Ozer HL. . 1996 Oncogene 12: 1847–1854.

  • McCarthy NJ, Whyte MK, Gilbert CS and Evan GI. . 1997 J. Cell Biol. 136: 215–227.

  • Nunez G, Benedict MA, Hu Y and Inohara N. . 1998 Oncogene 17: 3237–3245.

  • Papas KK, Sun L, Roos ES, Gounarides JS, Shapiro M and Nalin CM. . 1999 FEBS Lett. 446: 338–342.

  • Prendergast GC. . 1999 Oncogene 18: 2967–2987.

  • Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y and Jacobson MD. . 1993 Science 262: 695–700.

  • Reed JC. . 1998 Oncogene 17: 3225–3236.

  • Reed JC. . 1999 Curr. Opin. Oncol. 11: 68–75.

  • Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM. . 1990 Cell 63: 1129–1136.

  • Schreiber E, Matthias P, Muller MM and Schaffner W. . 1989 Nucleic Acids Res. 17: 6419.

  • Schreiber M, Kolbus A, Piu F, Szabowski A, U MH-S, Tian J, Karin M, Angel P and Wagner EF. . 1999 Genes Dev. 13: 607–619.

  • Schwartzberg PL. . 1998 Oncogene 17: 1463–1468.

  • Sherr CJ. . 1998 Genes Dev. 12: 2984–2991.

  • Shimizu Y and Hunt III SW. . 1996 Immunol. Today 17: 565–573.

  • Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM and Kroemer G. . 1999 Nature 397: 441–446.

  • Vercammen D, Brouckaert G, Denecker G, Van de Craen M, Declercq W, Fiers W and Vandenabeele P. . 1998 J. Exp. Med. 188: 919–930.

  • Vogt PK and Bos TJ. . 1990 Adv. Cancer Res. 55: 1–35.

  • Wajant H, Johannes FJ, Haas E, Siemienski K, Schwenzer R, Schubert G, Weiss T, Grell M and Scheurich P. . 1998 Curr. Biol. 8: 113–116.

  • Welham MJ and Wyke JA. . 1988 J. Virol. 62: 1898–1906.

  • White E. . 1996 Genes Dev. 10: 1–15.

  • Wisdom R, Johnson RS and Moore C. . 1999 EMBO J. 18: 188–197.

  • Xiang J, Chao DT and Korsmeyer SJ. . 1996 Proc. Natl. Acad. Sci. USA 93: 14559–14563.

  • Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X. . 1997 Science 275: 1129–1132.

  • Yao R and Cooper GM. . 1995 Science 267: 2003–2006.

  • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF. . 1998 Genes Dev. 12: 2424–2433.

Download references

Acknowledgements

The authors wish to thank the following for provision of reagents; P Vogt, S Hughes, H Wajant, D Lane and M Frame, and E Black, D Riley and J Wyke for comments on the manuscript. This work was supported by the Cancer Research Campaign (CRC).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

MacLaren, A., Clark, W. & Gillespie, D. v-Jun sensitizes cells to apoptosis by a mechanism involving mitochondrial cytochrome C release. Oncogene 19, 5906–5918 (2000). https://doi.org/10.1038/sj.onc.1203954

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203954

Keywords

This article is cited by

Search

Quick links